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SteatosisAlcohol consumption exacerbates alcoholic liver disease by attenuating the activity of AMP-activated protein
kinase (AMPK). AMPK is activated by fenoﬁbrate, a peroxisome proliferator-activated receptor α (PPARα) ago-
nist, and inhibited by direct interaction with cereblon (CRBN), a component of an E3 ubiquitin ligase complex.
Based on these preliminary ﬁndings, we investigated that CRBN would be up-regulated in the liver by alcohol
consumption and that CRBN deﬁciency would ameliorate hepatic steatosis and pro-inﬂammatory responses in
alcohol-fed mice by increasing AMPK activity. Wild-type, CRBN and PPARα null mice were fed an alcohol-
containing liquid diet and administered with fenoﬁbrate. Gene expression proﬁles and metabolic changes
were measured in the liver and blood of these mice. Expression of CRBN, cytochrome P450 2E1 (CYP2E1),
lipogenic genes, pro-inﬂammatory cytokines, serum alanine aminotransferase (ALT), and aspartate aminotrans-
ferase (AST) were increased in the Lieber–DeCarli alcohol-challengedmice. Fenoﬁbrate attenuated the induction
of CRBN and reduced hepatic steatosis and pro-inﬂammatory markers in these mice. Ablation of the gene
encoding CRBN produced the same effect as fenoﬁbrate. The increase in CRBN gene expression by alcohol and
the reduction of CRBN expression by fenoﬁbrate were negated in PPARα null mice. Fenoﬁbrate increased the re-
cruitment of PPARα on CRBN gene promoter in WT mice but not in PPARα null mice. Silencing of AMPK
prevented the beneﬁcial effects of fenoﬁbrate. These results demonstrate that activation of PPARα by fenoﬁbrate
alleviates alcohol-induced hepatic steatosis and inﬂammation by reducing the inhibition of AMPKbyCRBN. CRBN
is a potential therapeutic target for the alcoholic liver disease.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Alcoholic liver disease (ALD) is a metabolic disturbance caused by
chronic alcohol overconsumption, often progressing from hepaticliver disease; ALT, alanine
ST, aspartate aminotransferase;
romatin immunoprecipitation;
450 7A1; CYP2E1, cytochrome
S, fatty acid synthase; Feno,
-6; IL-1β, interleukin-1 β; PAI-
proliferator-activated receptor
-1c, sterol regulatory element
is factor-α; WT, wild type.
st@knu.ac.kr (S.-E. Lee),steatosis to steatohepatitis, ﬁbrosis, cirrhosis, and even hepatocellular
carcinoma [1]. It is a major cause and/or risk factor for chronic liver
disease in developing and Western countries [1,2]. Alcohol stimulates
hepatic fat accumulation by up-regulating sterol regulatory element
binding protein-1c (SREBP-1c) and fatty acid synthase (FAS). At the
same time, alcohol attenuates fatty acid oxidation by down-regulation
of peroxisome proliferator-activated receptor α (PPARα), sirtuin 1
(SIRT1), and several nuclear receptors [1,3–5]. In addition, alcohol
causes oxidative stress, lipotoxicity, endoplasmic reticulum stress, and
pro-inﬂammatory cytokine release and eventually leads to alcoholic
steatohepatitis, including severe fatty liver, inﬂammatory inﬁltrate
and hepatocellular damage [1,2,6].
PPARα is a member of the nuclear receptor superfamily that func-
tion as transcription factors for regulating metabolic processes such as
inﬂammation, insulin sensitivity, glucose, and lipid metabolism [7].
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is expressed primarily in the liver, heart, kidney and intestine [7,8].
Transcriptional regulation is achieved by the binding of PPAR/retinoid
X receptor heterodimers to PPAR response elements (PPREs) in target
gene promoters [7–9]. Fenoﬁbrate, a PPARα agonist, is a potent drug
used for treating dyslipidemia [10]. Moreover, fenoﬁbrate improves
hepatic steatosis and reduces pro-inﬂammatory cytokines in hepatic
insulin resistance [11,12]. Our previous studies have shown that
fenoﬁbrate inhibits pro-inﬂammatory cytokines and pro-ﬁbrotic
markers by activating AMP-activated protein kinase (AMPK) in the
progressive ﬁbrotic steatohepatitis mouse model [13].
Cereblon (CRBN), known to be associatedwith amild formofmental
retardation, interacts with the calcium-activated potassium channels
and voltage-gated chloride channel [14]. Moreover, CRBN is a major
target for thalidomide-mediated teratogenicity and a component of
the E3 ubiquitin ligase complex [15]. In recent studies, we demonstrated
that CRBN directly interacts with AMPK and its deﬁciency ameliorates
high-fat diet-induced obesity and insulin resistance by activating
AMPK in the liver [14,16]. AMPK acts as amajor sensor of cellular energy
balance and is a key regulator of metabolic homeostasis [17]. In addi-
tion, AMPK is activated in response to a variety of physiological stimuli,
pharmacological agents, hormones, oxidative stress, exercise, resvera-
trol, metformin, adiponectin, and leptin [18]. On the other hand, alcohol
consumption exacerbated alcoholic liver injury by attenuating the
activities of AMPK or SIRT1 [1,2,4,19]. Although CRBN regulates AMPK
in vitro and CRBN deﬁciency preserves metabolic homeostasis by
enhancing AMPK activity, a connection between the CRBN-AMPK
signaling system and alcoholic liver disease has not been investigated.
In this study, we demonstrate that elevation of CRBN caused by
chronic alcohol challenge is PPARα dependent. Moreover, disruption
of the gene encoding CRBN and treatment with fenoﬁbrate ameliorate
alcoholic liver disease by stimulating AMPK. Our ﬁndings suggest that
loss of CRBNmay provide a novel approach to prevent the pathological
progression of hepatic diseases caused by chronic alcohol exposure
as well as the potential therapeutic strategy for the prevention of
alcohol-mediated metabolic dysfunction.
2. Materials and methods
2.1. Animal experiments
Male wild-type C57BL/6J (WT) mice, PPARα null mice, and CRBN
null mice were used as described previously [13,16]. For chronic alco-
holic liver injury challenge, WT and CRBN null mice, weighing 20–30 g
at 8 weeks of age were divided into 3 groups: 1) the control liquid
diet in which alcohol was substituted isocalorically with maltose
dextrin gavage for 4 weeks (n = 5), 2) Lieber–DeCarli alcohol liquid
diet (Research Diets, New Brunswick, NJ, USA) with 5% alcohol (36%
alcohol-contained calories) gavage for 4 weeks (n = 7), and
3) Lieber–DeCarli alcohol liquid diet-treated with daily fenoﬁbrate
(Sigma-Aldrich, St. Louis, MO, USA, 100 mg/kg body weight) gavage
for last 2 weeks (n= 8), as described previously [20]. In some experi-
ments,WT and PPARα null micewere fedwith the Lieber–DeCarli alco-
hol liquid diet with or without 5% alcohol for 4 weeks (n=5–8/group).
For fenoﬁbrate (100 mg/kg) stimulation experiments, WT mice and
PPARα null mice were orally administered with fenoﬁbrate (Sigma-
Aldrich) for 5 days (n=5–8/group). In other experiments, an adenovi-
ral delivery system (Ad-DN AMPK) was injected by tail-vein into WT
mice (1 × 109 plaque-forming units, pfu) which were then exposed to
alcohol (6 g/kg body weight, n = 7) and fenoﬁbrate (100 mg/kg, n =
8) for 5 days. To ablation PPARα, WT mice were intravenously injected
with lentivirus short hairpin PPARα (sh PPARα, a single dose of 1 × 109
transducing units (TU) per ml). Mice were then fed with fenoﬁbrate
once-daily for 5 days. At the end of the liquid diet feeding periods, the
mice were euthanized with CO2, at which time liver weight, body
weight, liver/body weight ratio, liver tissues, and blood samples werecollected. All animal studies and protocolswere approved by the Institu-
tional Animal Use andCare Committee (IAUCC) of theGwangju Institute
of Science and Technology.
2.2. Biochemical assays
Serum samples were immediately prepared after the collection of
blood from the mice. Blood glucose levels of all mice were measured
with Glucostix AccuCheck (Roche Diagnostics, Mannheim, Germany),
and blood ethanol levels were quantiﬁed with Ethanol assay kit
(Sigma-Aldrich). Serum levels of alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), and cholesterol were determined with an
automated blood analyzer (AU400; Olympus, Tokyo, Japan) [21]. Total
adiponectin levels were measured using a commercial ELISA kit from
R&D Systems (Minnesotapolis, MN, USA), and insulin levels were ana-
lyzed with the insulin enzyme-linked immunosorbent assay test kit
(Mercodia, Uppsala, Sweden). Hepatic and serum bile acid (BA) were
measured with Bile acid L3K assay kit (Cell Biolabs, Inc., San Diego, CA,
USA). Serum cytokine concentrations were measured using a BD
Cytometry Bead Array (BD Bioscience, San Jose, CA, USA) in accordance
with the manufacturer's instructions, as described previously [21].
2.3. Measurement of hepatic and serum TG contents
Total TG levels in liver were analyzed using Inﬁnity reagents
(Thermo DMA, Louisville, CO, USA), according to the manufacturer's pro-
tocol, as mentioned previously [21,22]. Serum TG levels were measured
using a commercially available determination kits (Sigma-Aldrich).
2.4. Histological analysis
For hematoxylin and eosin (H & E) staining, liver tissue samples
were ﬁxed with 4% paraformaldehyde and embedded with parafﬁn, as
described previously [21,22]. Liver sections (4–5 μm) were performed
with H & E staining according to the standard procedures. Liver histology
was measured using the Digital Pathology Service-Aperio ImageScope
v12 (SeongKohn Traders' Corp., Seoul, Republic of Korea).
2.5. Western blot analysis
Livers were harvested and extracted forWestern blot analysis accord-
ing to methods described previously [23]. Membranes were probed with
phospho-AMPK (Thr172), AMPK, and FAS (Cell Signaling Technology,
MA, USA), PPARα, β-actin (SantaCruz Biotechnology, CA, USA), and
then developed using an ECL Western blot detection kit (Amersham
Bioscience, Piscataway, NJ, USA). The generation of the CRBN antibody
was described previously [14].
2.6. Plasmids, cell culture, and transient transfection
The reporter gene for CRBN was described previously [24]. Expres-
sion vector of PPARαwasmentioned previously [25]. The point mutant
form of CRBN-Luc was generated with the QuikChange II site-directed
mutagenesis kit (Stratagene, La Jolla, CA, USA), as described previously
[23]. The following primers: CRBN, forward 5′-AACAGTGGGTACTTCC
AGAC-3′ and reverse 5′-GTCTGGAAGATCCCACTGTT-3′. All constructs
were conﬁrmed by DNA sequencing. AML-12 cells (immortalized
mouse hepatocytes) were cultured in DMEM/F-12medium (Gibco-BRL,
Grand Island, NY, USA) supplemented with 10% FBS, insulin–
transferrin–selenium (Gibco-BRL), dexamethasone (40 ng/ml, Sigma-
Aldrich), and antibiotics in a humidiﬁed atmosphere containing 5%
CO2 at 37 °C (23). Transient transfection assays were conducted using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer's instruction, as previously described [13].
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Adenovirus expressing dominant-negative mutant AMPK (DN-
AMPK) was prepared as described previously [13,23]. Brieﬂy, the
cDNA encoding DN-AMPK (Asp157 to alanine in α1-AMPK and Lys45
to arginine α2-AMPK) was inserted into the EcoRI/XhoI sites of the
pAdTrack-CMV shuttle vector. The recombinant vector was then
electroporated into BJ5183 cells containing the AdEasy adenoviral
vector to exert the recombinant adenoviral plasmid. Adenovirus was pu-
riﬁed by the Adeno-XMaxi Puriﬁcation kit (Clontech,Mountain View, CA,
USA). Recombinant lentiviral system of PPARα-targeted short hairpin
RNA (shRNA) was purchased from Dharmacon (Lafayette, CO, USA).
2.8. RNA isolation and quantitative real-time PCR (qPCR) analysis
Total RNA, isolated by TRIzol reagent (Invitrogen), in accordance
with the manufacturer's instructions, was used for qPCR analysis as
described previously [13,16,20,23,25]. cDNA was synthesized using
the Maxima® First Strand cDNA Synthesis kit (Fermentas, Vilnius,
Lithuania). The mRNA levels were measured using the Power SYBR®
Green PCR Master Mix kit (Applied Biosystems, Warrington, UK) and
the StepOne™ Real-time PCR system (Applied Biosystems). The
sequences of all used primers were available on request. All data were
normalized to ribosomal L32 expression.
2.9. Chromatin immunoprecipitation (ChIP) Assay
In vivo ChIP assay was performed as described previously [23,25].
Soluble chromatin was subjected to immunoprecipitation using anti-
PPARα antibody (SantaCruz Biotechnology). Unrelated IgG was used a
negative control for immunoprecipitation. After puriﬁcation, DNA
samples were quantiﬁed by PCR using primers encompassing theFig. 1. Alcohol-mediated up-regulation of CRBN gene expression and alcoholic liver disease is r
liquid diet for 4 weeks and also treated with fenoﬁbrate (100 mg/kg) by oral gavage during
blot analysis with various antibodies. (B) Serum levels of pro-inﬂammatory cytokines and hep
vs. untreated control (CON) or EtOH-fed mice.mouse CRBN gene promoter. The speciﬁc primers used for PCR was as
follows: CRBN promoter, forward 5′-TCTGCTATATTCCAACGGCCC-3′
and reverse 5′-GGACAAGAAACCCAAAGTTA-3′.
2.10. Statistical analysis
Data calculation and statistical analysis were performed using
GraphPad Prism 3–5.0 software. The statistical signiﬁcance of differ-
ences between groups was determined with Student's t test and multi-
ple comparisonswere analyzed using one-wayANOVAunder treatment
and experiment as factors. All data are presented as means ± S.E.M.
Values of P b 0.05 were considered to be statistically signiﬁcant.
3. Results
3.1. Alcohol-induced CRBN gene expression and alcoholic liver disease are
regulated by fenoﬁbrate
Several studies have shown that chronic alcohol challenge elevates
fat accumulation via up-regulation of lipogenic genes and increases in
pro-inﬂammatory cytokines [1,2,6]. Our recent studies have demon-
strated that disruption of the CRBN gene enhances hepatic AMPK activ-
ity and ameliorates high-fat diet-induced obesity and insulin resistance
in mice [14,16]. Here, we investigated the possible link between CRBN
and alcoholic liver disease with mice fed the Lieber–DeCarli alcohol liq-
uid diet. As shown in supplementary Fig. 1, alcohol feeding signiﬁcantly
elevated the expression of the CRBN gene along with the expected
increase in cytochrome P450 2E1 (CYP2E1), CYP7A1, lipogenic
(SREBP-1c and FAS), Fyn, b-cell translocation gene 2 (BTG2), and pro-
inﬂammatory cytokine (IL-6, TNF-α, and IL-1β) genes. Interestingly,
mRNA levels of PPARα and SIRT1 are markedly reduced in the livers
of mice fed with alcohol when compared with the control groups.egulated by fenoﬁbrate. (A) Male C57BL/6 (WT) mice were fed the Lieber–DeCarli alcohol
the last 2 weeks of alcohol challenge (EtOH). Tissue extracts were analyzed by Western
atic TG levels were measured. n= 5–8 mice per group. *P b 0.05, **P b 0.01, ***P b 0.001
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fenoﬁbrate, we administered fenoﬁbrate into alcohol-challenged WT
mice. Fenoﬁbrate markedly diminished alcohol-mediated induction of
CRBN and FAS by up-regulating AMPK activity and also reduced the
levels of pro-inﬂammatory cytokines and hepatic TG (Fig. 1B and C).
Treatments with the PPARα agonists (Wy-14643) also promoted a
signiﬁcant increase in AMPK activation (data not shown), consistent
with previous reports [26]. Overall, these ﬁndings suggest that alcohol
feeding increases CRBN gene expression and that fenoﬁbrate improves
alcoholic liver disease via AMPK stimulation.
3.2. Disruption of CRBN ameliorates alcoholic liver disease
As a result of AMPKactivation, CRBNdeﬁciency produces a beneﬁcial
effect upon hepatic steatosis and insulin resistance caused by high-fat
diet-fed mice [16]. Therefore, we hypothesized that CRBN may also be
required for chronic alcoholic liver disease and that CRBN may regulate
the expression of lipogenic genes and pro-inﬂammatory responses by
controlling the AMPK signaling system. As shown in Fig. 2A, alcohol
challenge of WT mice signiﬁcantly elevated gene expression of CRBN,Fig. 2. CRBN null mice protect alcoholic liver disease. WT and CRBN null mice were fed the Lie
indicated primers. (B) Tissue extracts weremeasured byWestern blot analysis with various an
and hepatic TG levels. n= 5–8 mice per group. *P b 0.05, **P b 0.01, ***P b 0.001 vs. untreatedCYP2E1, plasminogen activator inhibitor-1 (PAI-1), pro-inﬂammatory
markers, and lipogenic enzymes. Alcohol challenge of WT mice also
markedly attenuated AMPK activity, consistent with previous ﬁndings
[1,4]. In contrast, these effects of alcohol challenge were totally absent
in CRBN null mice (Fig. 2B). Likewise, serum alanine aminotransferase
(ALT), aspartate aminotransferase (AST), pro-inﬂammatory cytokines,
hepatic TG, and hepatic cholesterol (CHO) levels were signiﬁcantly
elevated in alcohol-challenged WT mice but not in alcohol-fed CRBN
null mice (Fig. 2C and D). As expected, liver weight and liver/body
weight ratio were signiﬁcantly elevated in alcohol-fedWTmice, where-
as these effects of alcohol challengewere disrupted in alcohol-fed CRBN
null mice (supplementary Fig. 2A). As shown supplementary Fig. 2B,
serum levels of TG, CHO, BA, insulin, and hepatic BA contents were
signiﬁcantly lower in alcohol-fed CRBN null mice than in alcohol-
challenged WT mice. No signiﬁcant differences in blood alcohol, blood
glucose concentrations, and body weight gain were observed in these
mice. Surprisingly, the concentration of adiponectin was markedly re-
duced in alcohol-fed WT mice and was restored in alcohol-fed CRBN
null mice. Overall, these results show that CRBN acts as a key player in
regulating alcohol-mediated metabolic changes.ber–DeCarli alcohol liquid diet for 4 weeks. (A) Total RNA was analyzed by qPCR with the
tibodies. (C) Serum levels of ALT and AST. (D) Serum levels of pro-inﬂammatory cytokines
WT or EtOH-fed WT mice.
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signaling network
We evaluated the physiological effects of fenoﬁbrate upon chronic
alcohol-fed WT and CRBN null mice. The elevation of CRBN, pro-
inﬂammatory markers, and lipogenic genes caused by alcohol feeding
was attenuated in fenoﬁbrate-fed WT mice, but remarkably, theFig. 3.Alcohol-mediatedmetabolic dysfunction is altered by fenoﬁbrate-CRBNpathway.WT and
was challenged by oral gavage for the last 2 weeks of alcohol feeding. (A) Total RNAwas analyze
hepatic TG levels. (C) Liver histology after hematoxylin and eosin staining in mouse liver. n=beneﬁcial effects of fenoﬁbrate were abolished in CRBN null mice
(Fig. 3A), consistent with data presented in Fig. 2. Thus, we further con-
ﬁrmed that the increase of pro-inﬂammatory cytokines and hepatic TG
levels in response to alcohol challenge was dramatically diminished in
fenoﬁbrate-treated WT mice and this phenomenon was completely
disrupted in CRBN null mice (Fig. 3B). In addition, we measured the
potential role of fenoﬁbrate on hepatic steatosis in alcohol-fed WT andCRBNnullmicewere fed the Lieber–DeCarli alcohol liquid diet for 4weeks and fenoﬁbrate
d by qPCRwith the indicated primers. (B) Serum levels of pro-inﬂammatory cytokines and
5–8 mice per group. *P b 0.05, **P b 0.01 vs. untreated WT or EtOH-fed WT mice.
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fat accumulation caused by alcohol feeding in the livers of WT mice
(Fig. 3C). Surprisingly, hepatic steatosis was prevented in CRBN null
mice and therefore no effect of fenoﬁbrate was observed in these mice
(Fig. 3C). Collectively, these ﬁndings suggest that blockade of CRBN
caused by fenoﬁbrate plays a pivotal role in ameliorating alcoholic
liver disease.
3.4. Fenoﬁbrate regulates CRBN gene expression by a PPARe-dependent
pathway
As expected, treatment of WT mice with fenoﬁbrate markedly
attenuated CRBN gene expression, and signiﬁcantly stimulated AMPK
activation in a dose-dependent manner (Fig. 4A). Similarly, fenoﬁbrate
enhanced the expression of PPARα and decreased CRBN gene expres-
sion in WT mice but these effects of fenoﬁbrate were abolished in
PPARα null mice (Fig. 4B and C). To conﬁrm whether the expression
of CRBN gene repressed by fenoﬁbrate is mediated by PPARα, we intro-
duced a knock-down systemof PPARα (lentivirus-shRNA PPARα) in the
liver of fenoﬁbrate-fed mice. As expected, knockdown of PPARα using
lentiviral system (sh PPARα) successfully attenuated the expression of
PPARα gene when compared with the control groups. Fenoﬁbrate
markedly reduced the change of CRBN protein level, whereas this effect
is rescued by silencing of PPARα (supplementary Fig. 3). Next, to verify
that PPARα is involved in the regulation of CRBN gene expression, we
assessed the potential role of PPARα from alcohol feeding in the liver
of WT and PPARα null mice. Expression of PPARα gene was strikingly
reduced in alcohol-fed WT mice and CRBN gene expression was signif-
icantly increased in these mice but this phenomenon was disrupted in
PPARα null mice (Fig. 4D). Taken together, these ﬁndings demonstrate
that fenoﬁbrate-mediated inhibition of CRBN is regulated by a PPARα-
dependent mechanism.
3.5. PPARe directly regulates CRBN gene transcription
Next, the fundamental molecular mechanism by which PPARα
controls CRBN gene transcription was explored. As shown in Fig. 5A,
the increase of CRBNgene promoter activity caused by alcohol exposure
was dramatically reduced by either fenoﬁbrate treatment or PPARα in aFig. 4. Expression of CRBN caused by alcohol ismediated by fenoﬁbrate-PPARα axis. (A)WTmic
treatment, liverswere harvested and extracted forWestern blot analysiswith the indicated anti
and PPARα nullmicewere orally fedwith orwithout fenoﬁbrate for 5 days. Total RNAwas analy
harvested from the mice of the indicated groups and subjected to Western blot analysis with th
liquid diet for 4 weeks. Total RNA was analyzed by qPCR with the indicated primers. n= 5–8dose-dependent manner. We evaluated the functional signiﬁcance of
the PPARα-binding region on the CRBN gene promoter in hepatocytes
using transient transfection assay. Alcohol-stimulated CRBN promoter
activity was also markedly repressed by either fenoﬁbrate treatment
or PPARα, and this phenomenon was abolished at a mutant form of
the PPARα region (Fig. 5B). To further conﬁrm the stimulation of DNA
binding of endogenous PPARα protein on the CRBN gene promoter,
we performed chromatin immunoprecipitation (ChIP) assay in the
livers of mice using PPARα antibody. As expected, fenoﬁbrate strongly
promoted PPARα occupancy on the CRBN gene promoter and there
was no signiﬁcant PPARα-occupancy observed in either alcohol-
exposed or PPARα null mice (Fig. 5C and D). These ﬁndings strongly
suggest that PPARα is a direct transcriptional regulator of CRBN.
3.6. Alcoholic liver disease is altered by the fenoﬁbrate-AMPK pathway
To determine whether fenoﬁbrate-AMPK signaling network is in-
volved in the regulation of alcoholic liver disease, we examined the cru-
cial role of AMPK under both alcohol exposure and fenoﬁbrate feeding
and overexpression of the dominant negative form of AMPK (Ad-DN
AMPK) in mouse liver. As expected, alcohol-mediated induction of the
pro-inﬂammatory responses and lipogenic genes was strikingly
reduced by fenoﬁbrate treatment, consistent with data presented in
Fig. 3. In contrast, the beneﬁcial effects of fenoﬁbrate were disrupted
by Ad-DN AMPK (Fig. 6A). Likewise, the increase of pro-inﬂammatory
cytokines and hepatic TG levels caused by alcohol exposure was dra-
matically attenuated by fenoﬁbrate treatment, and this phenomenon
was also abolished by Ad-DN-AMPK (Fig. 6B). Overall, these results
demonstrate that alcohol-mediated hepatic disease is mediated by a
fenoﬁbrate-AMPK-dependent pathway.
4. Discussion
In the present study, we delineated the potential role of CRBN on
chronic alcohol challenge inmouse livers and explored the fundamental
molecular mechanism responsible for alcoholic liver disease. For the
ﬁrst time, we provide evidence that alcohol challenge increases CRBN
gene expression by attenuating the PPARα-dependent pathway, and
that treatment with fenoﬁbrate reduces hepatic steatosis and pro-ewere administered fenoﬁbrate (Feno) at the indicated concentrations. Six hours after the
bodies. Protein levelswere normalized to total form antibody and/or β-actin levels. (B)WT
zed by qPCRwith the indicated primers. (C) Tissue extracts were isolated from liver tissue
e indicated antibodies. (D) WT and PPARα null mice were fed the Lieber–DeCarli alcohol
mice per group. *P b 0.05, **P b 0.01 vs. untreated WT or EtOH-fed WT mice.
Fig. 5.PPARα is a direct regulator of CRBNgene transcription. (A) AML-12 cellswere transfectedwith the indicated reporter gene andPPARα, and then treatedwith either alcohol (50mM)
or fenoﬁbrate (50 μM) for 6 h. (B) AML-12 cells were transfected with wild-type (wt), mutant form of CRBN gene promoter (mt), and PPARα, and then treated with either alcohol or
fenoﬁbrate. *P b 0.05 vs. untreated control or EtOH-treated cells. (C) ChIP assay for the recruitment of PPARα on the CRBN gene promoter. WTmice were fed the Lieber–DeCarli alcohol
liquid diet for 4 weeks and also treated with fenoﬁbrate by oral gavage during the last 2 weeks of alcohol challenge (EtOH). (D)WT and PPARα null mice were orally fed with or without
fenoﬁbrate for 5 days. Soluble chromatin was immunoprecipitated with PPARα antibody or IgG. n= 5–8 mice per group. *P b 0.05 vs. untreated WT mice.
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but not in CRBN null mice. Finally, the beneﬁcial effect of fenoﬁbrate
caused by alcohol challenge was disrupted by silencing of AMPK.
Collectively, our current ﬁndings suggest that CRBN deﬁciency
ameliorates alcoholic liver disease by attenuating hepatic steatosis and
inﬂammation as well as enhancing AMPK activity.
Chronic alcoholic liver disease is characterized by hepatic steatosis,
overproduction of pro-inﬂammatory cytokines, and severe liver injury
[1,2]. Alcohol challenge up-regulates lipogenic genes and down-
regulates PPARα gene expression and AMPK activity, leading to an
increase of lipogenesis and inﬂammation and a decrease of fatty acid
oxidation [1–3,6]. However, the correlation between chronic alcohol
challenge and the beneﬁcial effects of hepatic CRBN deﬁciency has not
yet been investigated. In this study, we have observed that alcohol-
induced hepatic disease ismediated by a PPARα-CRBN signaling system
in mouse liver. Indeed, our ﬁndings demonstrated that alcohol chal-
lenge signiﬁcantly elevated CRBN gene expression via the reduction of
PPARα along with subsequent alleviation of AMPK activation (Figs. 1,
2, 4, and supplementary Fig. 1). Based on these ﬁndings, we speculate
that the attenuation of CRBN by PPARα activators may provide protec-
tive effects on alcohol-mediated hepatic dysfunction by stimulating
AMPK via the PPARα-CRBN signaling network.
Fyn kinase is a negative regulator of AMPK [27,28]. As a consequence
of greater AMPK activity, Fyn kinase null mice display greater fatty acid
oxidation, energy expenditure, and insulin sensitivity and these mice
are protected against hepatic steatosis caused by chronic alcohol con-
sumption [27,29]. Moreover, the SIRT1-AMPK network regulates hepatic
steatosis and the production of pro-inﬂammation cytokines in alcohol-
fed mice [4,30–32]. Our current study demonstrates that dysregulation
of AMPK caused by the alcohol-CRBN axis (Figs 1 and 2) markedly exac-
erbates hepaticmetabolic disease in alcohol-challengedmouse liver, con-
sistentwith previous reports. Remarkably,we observed the stimulation ofFyn and attenuation of SIRT1 in alcohol-fed mice compared to those of
control (supplementary Fig. 1). Therefore, we suggest that the down-
regulation of CRBN and/or the up-regulation of AMPK may provide
beneﬁcial effects in hepatic metabolic dysfunction by alcohol challenge.
However,we cannot exclude the possibility that alcoholmay also be asso-
ciated with Fyn kinase, SIRT1, and other unknown metabolic key regula-
tors to drive alcoholic-mediated hepatic disease.
We previously found that fenoﬁbrate alleviates pro-ﬁbrotic and
pro-inﬂammatory responses by stimulating AMPK activity in a PPARα-
independentmanner [13,33]. In this study, we conﬁrmed that fenoﬁbrate
regulates metabolic target genes through PPARα-AMPK axis in alcohol-
challenged mouse liver. Indeed, our current results demonstrate that
the increase of AMPK activation by fenoﬁbrate strikingly down-
regulated alcohol-induced hepatic steatosis and pro-inﬂammatory cyto-
kine responses. The protective effects of fenoﬁbrate were effectively
abolished by silencing of AMPK (Fig. 6). The elevated hepatic steatosis
and pro-inﬂammatory markers by alcohol exposure were markedly
attenuated by stimulating PPARα-AMPK signaling pathway in
fenoﬁbrate-fed mice (Figs. 1, 4 and 6). Therefore, fenoﬁbrate may protect
against alcoholic liver disease via two different pathways. The ﬁrst
pathway is a PPARα-independent manner by activating orphan nuclear
receptor small heterodimer partner, involving the progressive ﬁbrosis
model and a systemic excessive sepsis model. The second pathway is a
PPARα-dependent manner by promoting AMPK stimulation under
chronic alcoholic liver disease following the Lieber–DeCarli alcohol liquid
diet. Thus, the activation of AMPK and/or other signaling pathway in re-
sponse to physiological stimuli and pharmacological agents like exercise,
resveratrol, and adiponectin [17,18,30,31,34] may be relevant to AMPK
and alcoholic liver disease.
Previous studies have shown that PPARα is a ligand-activate tran-
scription factor and stimulates the transcription of target genes involved
in inﬂammation, glucose and lipid metabolism [7,8,25,35]. On the other
Fig. 6. Alcoholic liver disease is altered by fenoﬁbrate-AMPK signaling network. (A) WT mice were tail-vein injected with Ad-DN-AMPK. Mice were then administered alcohol and
fenoﬁbrate once-daily for 5 days. Total RNA was analyzed by qPCR with the indicated primers. (B) Serum levels of pro-inﬂammatory cytokines and hepatic TG levels. n = 5–8 mice
per group. *P b 0.05, **P b 0.01, ***P b 0.001, and #P b 0.05 vs. untreated control or EtOH-fed mice, and EtOH- and Feno-fed mice.
Fig. 7. Schematic model depicting the role of CRBN in alcoholic liver disease. Alcohol, a
major stimulus leading to alcoholic liver disease, elevates steatosis and inﬂammation by
up-regulating CRBN and subsequently causes alcoholic liver disease by attenuating
AMPK activation. Fenoﬁbrate, a PPARα agonist, effectively disrupts the alcohol-CRBN net-
work and ameliorates alcoholic liver disease by enhancing AMPK activity.
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ating the transcriptional activity of other target genes, including
C/EBPβ, NF-κB, and AP-1 [36–38]. Based on these ﬁndings, we elucidat-
ed a potential link between PPARα and CRBN gene regulation in the
liver of alcohol-challenged mice. As expected, CRBN gene expression
was markedly diminished in fenoﬁbrate-exposed WT mice, and this
phenomenon was abolished in PPARα null mice (Fig. 4). Alcohol signif-
icantly increased CRBN gene transcription, and this effect was directly
repressed by PPARα (Fig. 5), which is consistent with previous reports
[36–38]. Therefore, our results suggest that the phenomenon of
negative gene regulation caused by PPARα is the novel molecular
mechanism responsible for alcohol-mediated induction of CRBN gene
expression. However, we cannot rule out the possible molecular mech-
anism that links the PPARα-CRBN signaling network and alcoholic liver
disease with unexplored transcriptional factors, co-regulators competi-
tion or recruitment, microRNAs, and other signaling molecules, which
contribute to the regulation of CRBN gene expression.
In conclusion, our current study suggests that the PPARα-CRBN-
AMPK signaling network is a critically important pathway in alcoholic
liver disease. We speculate that the loss of CRBN may ameliorate
alcohol-mediated hepatic steatosis and inﬂammation through the
fenoﬁbrate-PPARα-AMPK signaling pathway. As described in the sche-
matic model (Fig. 7) the down-regulation of CRBN by fenoﬁbrate and/
or CRBN disruption induces beneﬁcial effects in alcoholic liver disease,
which suggest a novel therapeutic strategy for the prevention and treat-
ment of alcohol-induced metabolic dysfunction.
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